Bispecific T-cell engagers are a new and innovative treatment for myeloma. Two bispecific antibodies Teclistamab and Talquetamab have been approved by the EMA for the treatment of myeloma. In October 2023 we treated our first myeloma patient with Teclistamab. She is tolerating the treatment extremely well.
Priory Hospital treats first patient with Teclistamab a bispecific antibody treatment for myeloma.
